Approval for modifications to the stan fetal heart rate classification and the stan simplified clinical guidelines.  The device, as modified, will be marketed under the trade name stan s31 fetal heart monitor and is indicated as an adjunct to fetal heart rate monitoring to determine whether obstetrical intervention is warranted when there is increased risk of developing metabolic acidosis.  The device is intended for use in patients with: 1) planned vaginal delivery; 2) >36 completed weeks gestation; 3) singleton fetus; 4) vertex presentation; and 5) ruptured amniotic membranes.